Brennecke et al. [69] showed that low IL-8 serum levels after chemotherapy correlated to clinical response in stage IV melanoma patients, whereas elevated serum levels of VEGF and FGF-2 persisted following the initial cytostatic administration. Here, VEGFA is linked to melanoma.